November 13th, 20264WARD Trial Aims to Build the Case for Mavorixafor in Primary Chronic NeutropeniaThe phase 3 4WARD trial is evaluating mavorixafor for reducing infection rates and raising neutrophil counts in patients with primary chronic neutropenia.Read more